(
A–B) K
+ (
A) or Cl
- (
B) flux is not observed in SARS-CoV-2 (CoV-2) Orf3a
2x-STREP-reconstituted vesicles (blue) as compared with the empty vesicle control (black, n=3) using 1:10 (n=3) (
A) or 1:25 (n=3) (
B) ratios of protein to lipids. The protonophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and K
+-permeable ionophore valinomycin (Val) are added as indicated (arrows). Error is represented as SEM. (
C) K
+ flux is not observed in SARS-CoV-1 Orf3a
2x-STREP-reconstituted vesicles (blue) as compared with the empty vesicle control (black, n=3) using a 1:25 (purple, n=3) or 1:100 (green, n=3) ratio of protein to lipids. Error is represented as SEM. (
D) Schematic of 90° light-scattering K
+ flux assay (
Brammer et al., 2014;
Stockbridge et al., 2012). CoV-2 Orf3a vesicles reconstituted in 200 mM K-glutamate are diluted into a hypertonic buffer containing 260 mM K-thiocyanate, resulting in vesicle shrinkage. If CoV-2 Orf3a is a K
+-selective viroporin, then the asymmetrical K
+ concentration should drive K
+ influx, leading to water absorption, vesicle swelling (green arrow) and a reduction of 90° light-scattering (green line, inset). If CoV-2 Orf3a is not a K
+-selective viroporin, then vesicles will not swell (gray arrow) and no change in 90° light-scattering should be observed (gray line, inset). The addition of Val (dotted line) leads to vesicle swelling and reduction of 90° light-scattering should be observed for all vesicles in the sample. Created with
Biorender.com. (
E–G) No difference in normalized K
+ influx is observed among SARS-CoV-2 Orf3a
2x-STREP reconstituted using 1:10 (
E, black) or 1:100 (
F, red) ratio of protein to lipids, and control vesicles (
G, blue).